---
schema_version: "secwatch.filing_event.v1"
accession: "0001567264-25-000093"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2025-09-10T23:59:59+00:00"
generated_at: "2026-05-17T06:59:46.286591+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Intensity Therapeutics pauses INVINCIBLE-4 enrollment after skin irritation; first Cohort A patient achieves pCR

## Summary
- First patient in Cohort A achieved pathological complete response after two INT230-6 doses plus immunochemotherapy.
- Cohort A patients received INT230-6 eight days apart followed by standard-of-care immunochemotherapy.
- Safety profile described as favorable, but localized skin irritation near tumor site observed in some patients.
- Enrollment paused to evaluate data and implement adjustments before reopening.

## SEC filing metadata
- accession: 0001567264-25-000093
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2025-09-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000156726425000093/0001567264-25-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000156726425000093/intensity-20250910.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001567264-25-000093
- JSON: https://secwatch.observer/filing/0001567264-25-000093.json
- Plain text: https://secwatch.observer/filing/0001567264-25-000093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.